Tango Therapeutics (TNGX) Return on Equity (2021 - 2025)
Historic Return on Equity for Tango Therapeutics (TNGX) over the last 5 years, with Q3 2025 value amounting to 0.68%.
- Tango Therapeutics' Return on Equity fell 1600.0% to 0.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.68%, marking a year-over-year decrease of 1600.0%. This contributed to the annual value of 0.58% for FY2024, which is 1700.0% down from last year.
- Per Tango Therapeutics' latest filing, its Return on Equity stood at 0.68% for Q3 2025, which was down 1600.0% from 0.96% recorded in Q2 2025.
- Over the past 5 years, Tango Therapeutics' Return on Equity peaked at 0.16% during Q4 2021, and registered a low of 8.7% during Q2 2021.
- Over the past 5 years, Tango Therapeutics' median Return on Equity value was 0.45% (recorded in 2024), while the average stood at 0.96%.
- Per our database at Business Quant, Tango Therapeutics' Return on Equity surged by 84100bps in 2022 and then tumbled by -5100bps in 2025.
- Tango Therapeutics' Return on Equity (Quarter) stood at 0.16% in 2021, then plummeted by -153bps to 0.41% in 2022, then rose by 7bps to 0.38% in 2023, then plummeted by -58bps to 0.61% in 2024, then dropped by -12bps to 0.68% in 2025.
- Its Return on Equity stands at 0.68% for Q3 2025, versus 0.96% for Q2 2025 and 0.72% for Q1 2025.